.png){kind=icon}
.png){kind=icon}
Return
Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study
.png){kind=icon}
OA
AI
T
Y
N
U
R
T
K
G
DOI：10.1002/bcp.70687.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
PCSK9 inhibitors reduce major cardiovascular events in randomized trials of atherosclerotic cardiovascular disease (ASCVD), but real-world neuropsychiatric safety remains uncertain.
Keywords:
atherosclerotic cardiovascular disease
neuropsychiatric disorders
PCSK9 inhibitors
real-world evidence
Journal
IF:
3
Papers:
8.5K
Citations:
1.8W
Organization
Cited Papers